Brookdale Senior Living Inc.
BKDBrookdale Senior Living Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup.
Biggest watch item: the price is already 47 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (47 weeks in). But the balance sheet is under water: net worth is negative, so shareholders sit behind everyone the company owes. What settles it: whether the business can earn its way back to positive equity before dilution or restructuring gets there first.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Brookdale Senior Living Inc. trades at $14.2, in a confirmed uptrend and 47 weeks into that stage. That is +9.8% against its own 200-day average. It sits at 75% of a 52-week range of $7 to $17. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 47 of stage 2. At $14.2 it trades +9.8% versus its 200-day average and sits at 75% of its 52-week range ($7–$17).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved −14% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Brookdale Senior Living Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Brookdale Senior Living Inc. at 0.9× its FY25 revenue of $3.2 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Brookdale Senior Living Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The return-on-capital curve is not shown — net worth is negative, so a return on capital is not a meaningful number in any basis. This is a distressed balance sheet, and the stage is read from the growth curves alone.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.9% | +4.1% | — | — |
| Stock price | +87.0% | +55.8% | +15.2% | −1.9% |
4-Factor Sector Score
39.3/100 — rank 25 of 30 in Medical Care Facilities · 61% evidence confidence
Brookdale Senior Living Inc. scores 39.3 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 25. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17 + 5 + 10 + 7.3 = 39.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Brookdale Senior Living Inc. reported $0.8 B of revenue in the Mar 26 quarter, −6.2% year on year. Over 4 years it has compounded at 3.7% a year. The last full year, FY25, came in at $3.2 B. The last four reported quarters add to $3.1 B.
FY25 revenue came in at $3.2 B (+1.9% on the year), capping 4 years at 3.7% compound. The latest quarter (Mar 26) printed $0.8 B, −6.2% year on year.
Pace check: the last four quarters averaged −0.6% growth against the decade's 3.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.6% over the last 4 quarters against +1.5%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Brookdale Senior Living Inc.'s operating margin is 6.6% in the Mar 26 quarter, +2.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −8.0% to 1.6%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 6.6%, +2.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −8.0%–1.6%.
Why the margin moved: operating margin went +2.9 pp year on year while gross margin went +1.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Brookdale Senior Living Inc. posted a net loss of $0.01 B in the Mar 26 quarter. The full FY25 year was a loss of $0.3 B. That loss is 1.3% of the quarter's revenue. The same quarter a year earlier lost $0.1 B. 11 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.3 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Brookdale Senior Living Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.2 B of operating cash against $−0.3 B of profit. After $0.2 B of capital spending, $0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $0.2 B against reported profit of $−0.3 B, leaving free cash of $0.0 B after $0.2 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Brookdale Senior Living Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 10.4% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Brookdale Senior Living Inc. earns a ROE of 650% in FY25. That is up from a trough of −95% in FY24. Return on invested capital clears the cost of that capital by −2.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −8.2% net margin on 0.54× asset turns.
FY25 ROE is 650%, recovered from a FY24 trough of −95% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −8.2% net margin × 0.54× asset turns × −148.75× balance-sheet leverage ≈ 658.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 2.4% − 5.1% = a −2.7 pp spread. The 5.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Brookdale Senior Living Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Brookdale Senior Living Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Brookdale Senior Living Inc.'s net worth is negative — it owes more than it owns — so a debt-to-equity ratio is not meaningful here. On the annual view that ratio went from 7.47 in FY21 to −138.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $5.5 B against shareholder equity of $−0.1 B — a debt-to-equity of −110.20. On the annual view, debt-to-equity went from 7.47 (FY21) to −138.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
15.9% of Brookdale Senior Living Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 6.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 15.9% of the float is sold short, and at typical trading volumes it would take about 6.9 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Brookdale Senior Living Inc.: the Z-score reads −0.22. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of −0.22 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads −0.22.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1AMN Healthcare Services, Inc.AMN | 64.5/100Thin evidence · provisional58% evidence | LEADER | 26.0/35 Revenue 19.8% · PAT — · OPM change 6.7 pp 62% evidence | 13.2/25 ROCE 6.9% · OPM 8.5% 76% evidence | 9.2/20 P/E 30.7× · PEG — 15% evidence | 16.1/20 RS sector 15.6% · RS bench 36.1% · 1Y 92.9%12 of 12 weeks ahead 70% evidence |
| Exact sum: 26 + 13.2 + 9.2 + 16.1 = 64.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Tenet Healthcare CorporationTHC | 64.4/100Thin evidence · provisional58% evidence | TURNING | 23.7/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.5/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.1/20 P/E 7.2× · PEG — 15% evidence | 13.1/20 RS sector -5.5% · RS bench 13.7% · 1Y 53%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 16.5 + 11.1 + 13.1 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Concentra Group Holdings Parent, Inc.CON | 60.1/100Mixed-positive evidence71% evidence | BREAKING OUT | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.8/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.2/20 P/E 15.4× · PEG — 15% evidence | 15.3/20 RS sector 0.9% · RS bench 19.9% · 1Y 43.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.8 + 10.2 + 15.3 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4PACS Group, Inc.PACS | 58.7/100Thin evidence · provisional56% evidence | BREAKING OUT | 21.9/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 14.4/20 RS sector 15% · RS bench 34% · 1Y 302.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 13.3 + 9.1 + 14.4 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Encompass Health CorporationEHC | 55.8/100Mixed-positive evidence81% evidence | BASING | 20.6/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.4/20 P/E 16.1× · PEG 0.68 65% evidence | 5.0/20 RS sector -25.7% · RS bench -10% · 1Y -6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 15.8 + 14.4 + 5 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemed CorporationCHE | 55.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.7/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.5/20 P/E 23.4× · PEG — 15% evidence | 12.6/20 RS sector -8.7% · RS bench 9.9% · 1Y 24%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 15.7 + 9.5 + 12.6 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Fresenius Medical Care AGFMS | 55.0/100Mixed-positive evidence81% evidence | TURNING | 21.6/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.4/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.8/20 P/E 11.9× · PEG 0.22 65% evidence | 6.2/20 RS sector -25.4% · RS bench -9.8% · 1Y -0.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.4 + 15.8 + 6.2 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Addus HomeCare CorporationADUS | 54.4/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.7/20 P/E 17.3× · PEG 0.78 65% evidence | 7.2/20 RS sector -21.4% · RS bench -4.9% · 1Y 3.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.7 + 7.2 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9LifeStance Health Group, Inc.LFST | 53.3/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.1/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 16.9/20 RS sector 10.2% · RS bench 29.9% · 1Y 134.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 5.8 + 8.5 + 16.9 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10agilon health, inc.AGL | 53.2/100Mixed-positive evidence61% evidence | LEADER | 18.4/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 87% · RS bench 109.7% · 1Y 334%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 4.8 + 10 + 20 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Healthcare Services Group, Inc.HCSG | 53.2/100Thin evidence · provisional52% evidence | FADING | 22.9/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.6/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.4/20 P/E 14.3× · PEG — 15% evidence | 9.3/20 RS sector -10.3% · RS bench 6.7% · 1Y 60.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 22.9 + 10.6 + 10.4 + 9.3 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12DaVita Inc.DVA | 53.0/100Mixed-positive evidence81% evidence | LEADER | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.0/20 P/E 14.3× · PEG 2.08 65% evidence | 15.2/20 RS sector 13.4% · RS bench 33.4% · 1Y 76.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8 + 15.2 = 53 · Decision use: Price leads the evidence: RS versus the benchmark is 33.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Acadia Healthcare Company, Inc.ACHC | 49.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 14.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.6/20 P/E 21.2× · PEG — 15% evidence | 17.3/20 RS sector 7.7% · RS bench 27.7% · 1Y 64.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 7.5 + 9.6 + 17.3 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 47.5/100Mixed-negative evidence81% evidence | LEADER | 16.5/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.9/20 P/E 20.3× · PEG 1.48 65% evidence | 10.9/20 RS sector 1.4% · RS bench 19.5% · 1Y 107.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.2 + 9.9 + 10.9 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Guardian Pharmacy Services, Inc.GRDN | 46.8/100Mixed-negative evidence64% evidence | TURNING | 17.2/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.6/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 8.3/20 RS sector -6.7% · RS bench 10.7% · 1Y 103%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 12.6 + 8.7 + 8.3 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16HCA Healthcare, Inc.HCA | 44.8/100Thin evidence · provisional58% evidence | BASING | 16.2/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 16.4/25 ROCE 6.9% · OPM 15% 76% evidence | 10.7/20 P/E 13.1× · PEG — 15% evidence | 1.5/20 RS sector -33.7% · RS bench -19.8% · 1Y 5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 16.4 + 10.7 + 1.5 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17The Pennant Group, Inc.PNTG | 44.7/100Mixed-negative evidence75% evidence | FADING | 20.4/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 11.1/20 RS sector -3.7% · RS bench 14.3% · 1Y 48.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.4 + 9.2 + 4 + 11.1 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aveanna Healthcare Holdings Inc.AVAH | 44.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 11.5/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 9.8/20 RS sector -14.2% · RS bench 3.6% · 1Y 52.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 11.8 + 11.4 + 9.8 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Universal Health Services, Inc.UHS | 44.3/100Thin evidence · provisional58% evidence | BASING | 16.4/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.1/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 2.5/20 RS sector -35.5% · RS bench -21.5% · 1Y -2.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 14.1 + 11.3 + 2.5 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Option Care Health, Inc.OPCH | 43.4/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 10.1/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -37.2% · RS bench -23.5% · 1Y -16%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 11.3 + 10.1 + 5 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Pediatrix Medical Group, Inc.MD | 43.3/100Mixed-negative evidence74% evidence | FADING | 17.5/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.2/25 ROCE 2.5% · OPM 8.7% 76% evidence | 9.9/20 P/E 10.4× · PEG 1.7 65% evidence | 5.7/20 RS sector -11.9% · RS bench 5.1% · 1Y 72.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 10.2 + 9.9 + 5.7 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22The Ensign Group, Inc.ENSG | 42.2/100Thin evidence · provisional58% evidence | BASING | 17.7/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.3/20 P/E 25.1× · PEG — 15% evidence | 3.0/20 RS sector -27.5% · RS bench -12.6% · 1Y 9.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 12.2 + 9.3 + 3 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.7/100Mixed-negative evidence75% evidence | 11.1/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.7/25 ROCE 2% · OPM 6.9% 76% evidence | 13.1/20 P/E 15.4× · PEG 0.93 65% evidence | 6.8/20 RS sector -22.8% · RS bench 1.5% · 1Y 9%0 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 11.1 + 9.7 + 13.1 + 6.8 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24InnovAge Holding Corp.INNV | 39.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 16.7/20 RS sector 20% · RS bench 39.9% · 1Y 227.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 16.7 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Brookdale Senior Living Inc.this pageBKD | 39.3/100Mixed-negative evidence61% evidence | TURNING | 17.0/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -10.3% · RS bench 6.1% · 1Y 97.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 5 + 10 + 7.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Ardent Health, Inc.ARDT | 39.2/100Mixed-negative evidence65% evidence | TURNING | 14.3/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.7/25 ROCE 1.9% · OPM 5.1% 76% evidence | 11.0/20 P/E 9× · PEG — 15% evidence | 5.2/20 RS sector -24.1% · RS bench -7.7% · 1Y -9.6%2 of 12 weeks ahead 70% evidence |
| Exact sum: 14.3 + 8.7 + 11 + 5.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Astrana Health, Inc.ASTH | 37.9/100Mixed-negative evidence81% evidence | FADING | 14.2/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.3/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 5.9/20 RS sector -10.4% · RS bench 6.4% · 1Y 27%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.3 + 10.5 + 5.9 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 36.7/100Mixed-negative evidence61% evidence | FADING | 13.9/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -31% · RS bench -15.8% · 1Y -33.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.2 + 10 + 5.6 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Sonida Senior Living, Inc.SNDA | 34.2/100Adverse evidence64% evidence | FADING | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 5.9/20 RS sector -11.4% · RS bench 5.4% · 1Y 58.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 5.9 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.3/100Thin evidence · provisional47% evidence | LEADER | 19.8/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.5/20 RS sector 18.2% · RS bench 37.9% · 1Y 168.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 5 + 10 + 13.5 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Brookdale Senior Living Inc.'s stock price today?
Brookdale Senior Living Inc. trades at $14.2, +87.0% over the past year. The company is valued at $3.0 B. The stock sits at 75% of its 52-week range of $7–$17, +9.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 47 weeks in. — as of 5 August 2026.
What were Brookdale Senior Living Inc.'s latest quarterly results?
Brookdale Senior Living Inc. reported revenue of $0.8 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.03. The operating margin was 6.6%, 2.9 pp higher than a year earlier. — as of 5 August 2026.
What is Brookdale Senior Living Inc.'s revenue?
Brookdale Senior Living Inc. reported revenue of $0.8 B in the Mar 26 quarter, −6.2% year on year. For the full FY25 fiscal year, revenue was $3.2 B (+1.9%). Over the last 4 years revenue compounded at 3.7% a year. — as of 5 August 2026.
What is Brookdale Senior Living Inc.'s profit?
Brookdale Senior Living Inc. earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.3 B. The operating margin ran 6.6% in the latest quarter. — as of 5 August 2026.
What is Brookdale Senior Living Inc.'s market cap?
Brookdale Senior Living Inc.'s market capitalisation is $3.0 B at a stock price of $14.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Brookdale Senior Living Inc. pay a dividend?
No — Brookdale Senior Living Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is Brookdale Senior Living Inc. performing?
Brookdale Senior Living Inc. is in a confirmed uptrend, 47 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
Is Brookdale Senior Living Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 47 of stage 2), trading +9.8% versus its 200-day average and at 75% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Brookdale Senior Living Inc. beating the market?
On recent form, yes — Brookdale Senior Living Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved −14% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Brookdale Senior Living Inc.'s stock price go up?
This page publishes no price forecast for Brookdale Senior Living Inc. What it measures instead: the stock price is $14.2, the price is in a confirmed uptrend 47 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Brookdale Senior Living Inc.?
Yes — short interest is 15.9% of Brookdale Senior Living Inc.'s tradable float, about 6.9 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is Brookdale Senior Living Inc.'s capex?
Brookdale Senior Living Inc. spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.2 B. — as of 5 August 2026.
What is Brookdale Senior Living Inc.'s cash flow?
Brookdale Senior Living Inc. generated $0.2 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.2 B of capital spending. Reported profit that year was $−0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is Brookdale Senior Living Inc.?
On the balance sheet, the Z-score reads −0.22 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is Brookdale Senior Living Inc. in its business cycle?
Brookdale Senior Living Inc.'s FY25 operating margin was 0.3%, against a 5-year band of −8.0%–1.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 6.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Brookdale Senior Living Inc. story?
Biggest watch item: the price is already 47 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Brookdale Senior Living Inc. a stock worth studying right now?
This is not investment advice. The machine read: Brookdale Senior Living Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup. The sharpest open question: whether the business can earn its way back to positive equity before dilution or restructuring gets there first. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.